These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 35269550)

  • 1. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
    Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19.
    Idris A; Davis A; Supramaniam A; Acharya D; Kelly G; Tayyar Y; West N; Zhang P; McMillan CLD; Soemardy C; Ray R; O'Meally D; Scott TA; McMillan NAJ; Morris KV
    Mol Ther; 2021 Jul; 29(7):2219-2226. PubMed ID: 33992805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in siRNA delivery.
    Sarisozen C; Salzano G; Torchilin VP
    Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.
    Itani R; Tobaiqy M; Al Faraj A
    Theranostics; 2020; 10(13):5932-5942. PubMed ID: 32483428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
    Saify Nabiabad H; Amini M; Demirdas S
    Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
    Mainini F; Eccles MR
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
    Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM
    Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Viral Vectors Any Good for RNAi Antiviral Therapy?
    Lundstrom K
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33092124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
    Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
    Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection.
    Supramaniam A; Tayyar Y; Clarke DTW; Kelly G; Acharya D; Morris KV; McMillan NAJ; Idris A
    J Microbiol Immunol Infect; 2023 Jun; 56(3):516-525. PubMed ID: 36934064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges.
    Won Lee J; Kyu Shim M; Kim H; Jang H; Lee Y; Hwa Kim S
    Adv Drug Deliv Rev; 2023 Oct; 201():115073. PubMed ID: 37657644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
    Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
    Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses.
    Sajid MI; Moazzam M; Cho Y; Kato S; Xu A; Way JJ; Lohan S; Tiwari RK
    Mol Pharm; 2021 Jun; 18(6):2105-2121. PubMed ID: 33945284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
    Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
    Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
    Revia RA; Stephen ZR; Zhang M
    Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.